InvestorsHub Logo
Followers 3
Posts 598
Boards Moderated 0
Alias Born 10/19/2016

Re: SJSTOCKSHARK post# 2303

Tuesday, 12/06/2016 2:35:20 PM

Tuesday, December 06, 2016 2:35:20 PM

Post# of 6401
You're right, SJ, some gleevec resistant patients will benefit from BP1001. This data comes from the phase 1 study so is old news and most importantly came from the first cohort with the low dose of 5 mg/kg.
Unfortunately, they have not yet started recruitment for patients in the CML 1b/2a study. We need new data. If they use the 60 mg dose, we could see amazing results.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent BPTH News